Atara Biotherapeutics, Inc.
ATRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,453 | $17,575 | $98,149 | $32,753 |
| % Growth | -80.4% | -82.1% | 199.7% | – |
| Cost of Goods Sold | $115 | $554 | $20,439 | $6,795 |
| Gross Profit | $3,338 | $17,021 | $77,710 | $25,958 |
| % Margin | 96.7% | 96.8% | 79.2% | 79.3% |
| R&D Expenses | $2,910 | $7,310 | $27,433 | $28,721 |
| G&A Expenses | $0 | $5,935 | $11,475 | $9,440 |
| SG&A Expenses | $3,975 | $5,935 | $11,475 | $9,440 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $579 | $0 | $0 |
| Operating Expenses | $6,885 | $13,824 | $38,908 | $38,161 |
| Operating Income | -$3,547 | $3,197 | $38,802 | -$12,203 |
| % Margin | -102.7% | 18.2% | 39.5% | -37.3% |
| Other Income/Exp. Net | -$728 | -$807 | -$792 | -$509 |
| Pre-Tax Income | -$4,275 | $2,390 | $38,010 | -$12,712 |
| Tax Expense | $28 | $3 | $0 | -$19 |
| Net Income | -$4,303 | $2,387 | $38,010 | -$12,693 |
| % Margin | -124.6% | 13.6% | 38.7% | -38.8% |
| EPS | -0.32 | 0.2 | 3.53 | -1.19 |
| % Growth | -260% | -94.3% | 396.6% | – |
| EPS Diluted | -0.32 | 0.19 | 3.5 | -1.19 |
| Weighted Avg Shares Out | 13,564 | 12,197 | 10,764 | 10,690 |
| Weighted Avg Shares Out Dil | 13,564 | 12,310 | 10,851 | 10,690 |
| Supplemental Information | – | – | – | – |
| Interest Income | $204 | $143 | $236 | $597 |
| Interest Expense | $909 | $972 | $1,017 | $1,017 |
| Depreciation & Amortization | $36 | $236 | $1,795 | $1,100 |
| EBITDA | -$3,330 | $3,598 | $40,822 | -$10,595 |
| % Margin | -96.4% | 20.5% | 41.6% | -32.3% |